S

Sanofi

Global pharma company; vaccines and R&D

Patient Education Liaison

Full-TimeUpdated on 10/23/2026Deadline 10/30/26
$122.3k - $176.6k
Mid, Senior
Bachelor's, Master's
Remote in USA
RemoteRemote in the United States; travel required 50%–75%.
Medical, Clinical & Veterinary

About the job

Requirements
  • A bachelor's degree in health care or life sciences, or equivalent, is required.
  • A minimum of 3–5 years of clinical experience in a related field is required.
  • Strong verbal and written communication, mediation, and problem-solving skills are required, including the ability to connect with patients, caregivers, and providers.
  • The ability to convey complex concepts clearly to clinical and non-clinical audiences is required.
  • Experience and demonstrated success working in a complex matrix to accomplish goals is required.
  • People skills demonstrating flexibility, persistence, creativity, empathy, and trust are required.
  • Strong business acumen and strategic thinking skills are required.
  • The role requires extensive travel (50%–75%).
Responsibilities
  • Lead strategy and execute communication and coordination of branded and unbranded education covering disease, inheritance, and product information for patients and families across the existing Rare Disease portfolio and potential future launches within the assigned territory.
  • Evaluate individual patients' educational needs and develop strategic, personalized action plans to deliver relevant education and support that addresses each patient's barriers and concerns and enhances understanding and engagement throughout their journey.
  • Facilitate patient education through individual, family, and group meetings and through patient organizations and communities, supporting efforts at regional and national levels as needed.
  • Develop and execute patient programming strategies that prioritize patient needs in key accounts, align programs with appropriate audiences, and tailor initiatives to optimize patient engagement and outcomes across therapeutic areas.
  • Conduct in-depth disease and product in-services for healthcare professionals in infusion settings, including home and outpatient settings, and coordinate with field team members as appropriate.
  • Build and maintain relationships with the Strategic Account Management cross-functional team, including Commercial, Medical, Marketing, and Case Management, to exchange insights and develop ideas for key account strategies; align patient education initiatives with business strategies and patient outcomes.
  • Analyze and use data to inform strategic decisions, prioritize initiatives across disease states and products, meet established key performance indicators, and adjust communication strategies and patient education efforts.
  • Document pertinent communication details accurately and consistently in the customer relationship management database, maintaining timely updates and data integrity.
  • Comply with company policies, industry standards, and legal and regulatory requirements, and coordinate the compliant exchange of patient-related information with internal and external stakeholders.
  • Seek opportunities to improve processes and outcomes and enhance patient support.
  • Complete administrative reports and projects in a timely manner.
  • Maintain expertise through continuing medical and scientific education, including symposia, scientific workshops, preceptorships, journal review, and internal training programs.
  • Use professional communication to foster working relationships with internal and external colleagues.
  • Provide caseload coverage outside the assigned territory as needed.
Desired Qualifications
  • Genetic counseling certification or nursing registration is preferred.
  • A Master of Science degree or another advanced medical or scientific degree is preferred.
  • Experience in the biotechnology or pharmaceutical industry is preferred.
  • Experience in Genetics, Neurology/Neuromuscular, Renal, or Hematology/Oncology is preferred.
  • Spanish language skills are preferred.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...